A Multi-center, Three-staged With Interim Analyses, Parallel, Randomized, Double-blind, fenofibrate-and Placebo-controlled Proof of Concept and Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma High-density Lipoprotein Cholesterol (HDLc) and Triglycerides of Eight Weeks Treatment With GW501516 in Otherwise Healthy Patients With Low HDLc, Mildly to Moderately Elevated Triglycerides, and Normal Low-density Lipoprotein Cholesterol (LDLc)
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs GW 501516 (Primary)
- Indications Low HDL cholesterol
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Aug 2007 Status changed from in progress to completed.
- 29 Oct 2005 New trial record.